BioSpace News Archive

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas Conference Call and Live Audio Webcast Scheduled for Today, August 12, 2020, at 4:30 p.m. ET HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today reported its corporate and financial results for the second quarter ended June 30, 2020. Financial Highl

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Business Highlights Announced exclusive license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in Greater China and South Korea;

NL-201 IND submission anticipated during fourth quarter of 2020 Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023 Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein